Corporate Update To Our Shareholders, Employees & Partners: 1 Cumberland rebounded strongly during 2014  returning to growth and profitability. We ended the  year with revenues growing 15% to $37 million and adjusted earnings of $6.3 million or $0.35 per share. Our financial profile remained strong. We ended  the year with $55 million in cash and investments,  and no debt. During 2014 the Company structured a  new senior credit facility for up to $20 million with  SunTrust Bank. We also arranged $2 million in new  funding for our research activities at CET, which  included an investment from our international  partner, China’s Gloria Pharmaceuticals. With the addition of our two newest products, our  revenue stream is now more diverse than ever  before. During 2014, we completed the acquisition  of  Vaprisol ®  just a few months after adding  Omeclamox ® -Pak  to our portfolio. We launched  active promotion of both brands in 2014 and are  encouraged by their initial contributions, as well as  the favorable response we have received from the  medical community. We secured and listed new patents for Acetadote  and Caldolor in 2014 and completed our two key  Caldolor pediatric studies. This important new  pediatric data will be the catalyst for an updated  labeling request to the FDA for the brand. I was pleased with our progress in 2014 and am  confident that our best days are ahead of us. I  would like to acknowledge and thank my colleagues  at Cumberland for all their fine efforts.  Meanwhile,  Kristalose ®  grew to be our largest  brand in 2014 following the successful launch of its  new positioning.  Acetadote ®  sales stabilized during  the year and remained an important contributor to  our business as we continued to maintain a majority  market share between shipments of the brand and  our Authorized Generic.  Caldolor ®  continued its  steady growth with additional hospitals stocking the  product every month and increasing pull through  sales in the stocked accounts. International sales  of our products grew during 2014, buoyed by strong  Caldolor sales in South Korea following its launch  there earlier in the year. Our strategy is to maximize the full potential of our  commercial brands and pursue opportunities to  further expand our portfolio through our business  development efforts and advancement of our  internal pipeline. We are confident that Cumberland  remains in a position to do just that, supported by  our strong financial position. Most importantly,  we remain focused on our mission of advancing  patient care through the delivery of high quality  pharmaceutical products.  Our strategy is to maximize the full potential of our  commercial brands and pursue opportunities to  further expand our portfolio through our business  development efforts and advancement of our  internal pipeline. With best wishes, A.J. Kazimi Chairman and  Chief Executive Officer